Take an objective view of your current viability
New worries should not distract executives from addressing rising costs and threats of consolidations
Medicare Advantage will take the greatest hit: Plans must reduce their medical costs by almost 25% over seven years just to maintain current profitability.
To address these challenges, plans should follow a three-pronged approach:
NEW WAY OF DOING BUSINESS
Firms in growth mode will also re-examine their business models. They may, for example, change their target customers and develop new offerings for them, including non-insurance products. To make decisions best suited for their market and risk tolerance, firms must develop an objective view of their organization's capabilities, an accurate model of their ecosystem, and a realistic prediction of likely future market scenarios.
The boldest firms are already moving toward a new way of doing business in which the health plan is an active partner of both providers and members. This represents a major departure from the current détente between payers and providers, with important implications for human capital, information systems and other investments.
Given the magnitude of the recent reforms, payers that blindly adhere to their current strategic plans could face stagnation or collapse. Firms that revisit their strategies, however, will be positioned to thrive in the new system as it evolves.
Jeff Gruen is a director at PRTM, a global consulting firm.
Cassandra Earley is an associate at PRTM.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
